Shivam Kumar

📈 Swing Trader & Stock Market Research
📊 Earnings • Breakouts • Watchlists
🏪 SME Reserch
🎓 CSE AI & DS Student
⚠️ Not SEBI Registered | Educational Only

[Shivam Kumar @ShivamKumar509]

The reason why you should follow me 👇

Every post I share is focused on helping traders make better decisions.

You’ll find:

• 📈 Swing Trading Setups
• 📊 Earnings Breakdown
• 🚀 Breakout Watchlists
• 📰 Corporate Announcements that matter
• 📚 Lessons I’m learning in the market

I’m here to build a trusted trading community—not to chase viral posts.

If you enjoy quality market research, you’re in the right place.

Let’s grow together. 📊

⚠️ Educational purposes only. Not SEBI Registered.

[Shivam Kumar @ShivamKumar509]

TRIVENI TURBINE CONCALL: FY27 GROWTH EXPECTED IN HIGH DOUBLE-DIGITS 🚀

Triveni Turbine’s latest concall commentary indicates a positive outlook for FY27, with growth expected to be stronger in the second half.

FY27 Growth:
Management remains confident of achieving both revenue and profit growth in FY27.

High Double-Digit Growth:
The company expects the extent of top-line and bottom-line growth to be at the higher end of double-digits.

Back-Ended Growth:
FY27 growth is expected to be back-ended, with stronger performance anticipated in H2 FY27.

PBT Margin:
Management believes PBT margins above 20% are sustainable over the medium to long term.

Margin Recovery:
Recovery in both absolute margins and margin percentages is expected in H2 FY27.

US Subsidiary:
The US subsidiary is targeted to break even during FY27, despite a significant Q1 loss, which management had anticipated.

Overall:
Strong H2 recovery, high double-digit growth and sustainable 20%+ PBT margins remain the key positives from the concall.

[Shivam Kumar @ShivamKumar509]

YATHARTH HOSPITAL CONCALL: 5,000 BEDS TARGET IN ~2.5 YEARS 🚀

Yatharth Hospital’s latest concall commentary highlights a strong growth and expansion outlook for FY27.

FY27 Revenue Growth: Management expects revenue growth to surpass last year’s growth.

EBITDA Margin:
FY27 EBITDA margin is expected to remain above 24%.

ARPOB Growth:
ARPOB is expected to grow 9–10% YoY in FY27 and beyond.

5,000-Bed Target:
The company expects to reach 5,000 beds in less than 3 years, potentially in around 2.5 years. Around 3,200 beds have already been announced.

New Hospital Margins:
New hospitals are expected to achieve 15–20% EBITDA margins within 15–18 months after breakeven and 25%+ within 2 years.

Expansion CapEx:
The next 1,800 beds are expected to require CapEx of around ₹75–80 lakh per bed.
Gurugram Hospital: CapEx is estimated at nearly ₹1 crore per bed.

Overall:
Strong ARPOB growth, aggressive bed expansion and improving margins remain key growth drivers for Yatharth Hospital going forward.

[Shivam Kumar @ShivamKumar509]

🚀 YATHARTH HOSPITAL Q1 FY27 — Strong Growth!

Q1 Quick Breakdown 📊

🔹 Net Profit: ₹47 Cr ⬆️ +12% YoY
🔹 Revenue: ₹393 Cr ⬆️ +51% YoY
🔹 EBITDA: ₹91.7 Cr ⬆️ +42% YoY
🔹 EBITDA Margin: 23.35% vs 25.02% YoY

📈 Revenue growth remains impressive, while EBITDA continues to scale strongly.

⚠️ Margin declined by ~167 bps — something to watch in the coming quarters.

[Shivam Kumar @ShivamKumar509]

⚡ GUJARAT ENERGY — Strong Q1 Performance

Q1 numbers show strong growth across key parameters:

🟢 Net Profit: ₹998 Cr vs ₹560 Cr YoY → +78%
🟢 Revenue: ₹9,670 Cr vs ₹5,924 Cr YoY → +63%
🟢 EBITDA: ₹1,295 Cr vs ₹770 Cr YoY → +68%
🟢 EBITDA Margin: 13.40% vs 13.00% → improved by 40 bps

Quick Take: Strong revenue growth is translating into even stronger profit growth, while margins remain stable-to-positive.

[Shivam Kumar @ShivamKumar509]

Current Market breadth (MB) Situtuions.

[Shivam Kumar @ShivamKumar509]

🚀 ZEN TECHNOLOGIES — BIG DEFENCE ORDER! 🇮🇳

🔥 Zen Technologies receives a ₹295 Cr order from the Ministry of Defence for the supply of simulators.

🔹 Order Value: ₹295 Cr
🔹 Client: Ministry of Defence
🔹 Product: Simulators
🔹 Positive for order book & future revenue visibility 📈

🇮🇳 Another major defence order strengthening Zen Technologies’ position in India’s defence ecosystem.

[Shivam Kumar @ShivamKumar509]

🚀 CHOICE INTERNATIONAL — Strong Q1 FY27!

Q1 Quick Breakdown 📊

🔹 Net Profit: ₹60.6 Cr ⬆️ +26% YoY
🔹 Revenue: ₹310 Cr ⬆️ +33% YoY
🔹 EBITDA: ₹105 Cr ⬆️ +27% YoY
🔹 EBITDA Margin: 33.83% vs 35.27% YoY
🔹 Margin change: -144 bps

📈 Strong revenue and profit growth, while EBITDA also remained healthy.

[Shivam Kumar @ShivamKumar509]

💎 PC JEWELLER — Strong Q1 FY27 Performance!

Q1 Quick Breakdown 📊

🔹 Net Profit: ₹222 Cr ⬆️ +37% YoY
🔹 Revenue: ₹877 Cr ⬆️ +21% YoY
🔹 EBITDA: ₹241 Cr ⬆️ +90% YoY 🚀
🔹 EBITDA Margin: 27.54% vs 17.56% YoY
🔹 Margin expansion: +998 bps 🔥

📈 Profitability is growing much faster than revenue, with a sharp improvement in EBITDA margins.

Is PC Jeweller showing signs of a strong turnaround? 👀

[Shivam Kumar @ShivamKumar509]

🔥 LLOYDS METALS & ENERGY — Massive Q1 Growth!

Q1 FY27 Quick Breakdown 📊

🔹 Net Profit: ₹1,530 Cr ⬆️ +141% YoY
🔹 Revenue: ₹5,353 Cr ⬆️ +125% YoY
🔹 EBITDA: ₹2,120 Cr ⬆️ +172% YoY
🔹 EBITDA Margin: 39.59% vs 32.81% YoY
🔹 Margin expansion: +678 bps 🚀

📈 Strong growth across revenue, EBITDA and profit — with margins expanding significantly.

Is Lloyds Metals entering a new growth phase? 👀

[Shivam Kumar @ShivamKumar509]

🚀 YATHARTH HOSPITAL Q1 FY27 — Strong Growth!

Q1 Quick Breakdown 📊

🔹 Net Profit: ₹47 Cr ⬆️ +12% YoY
🔹 Revenue: ₹393 Cr ⬆️ +51% YoY
🔹 EBITDA: ₹91.7 Cr ⬆️ +42% YoY
🔹 EBITDA Margin: 23.35% vs 25.02% YoY

📈 Revenue growth remains impressive, while EBITDA continues to scale strongly.

⚠️ Margin declined by ~167 bps — something to watch in the coming quarters.

[Shivam Kumar @ShivamKumar509]

🚀 WOCKHARDT — Strong Q1 FY27 turnaround.

Q1 FY27 Quick Breakdown 📊

🔹 Net Profit: ₹106 Cr 🟢 vs ₹90 Cr loss YoY
🔹 EBITDA: ₹192 Cr ⬆️ vs ₹72 Cr YoY
🔹 EBITDA Margin: 20.7% vs 9.8% YoY
🔹 Margin expansion: +10.9 percentage points YoY

Big takeaway:
Wockhardt has moved from a loss-making Q1 to a profitable quarter, with a sharp improvement in operating profitability. 📈

[Shivam Kumar @ShivamKumar509]

🚆 BEML: ₹40,000 Cr Order Prospects! 🔥

BEML management shares a strong FY27 outlook:

🔹 FY27 Order Inflow: Expected at ₹20,000 Cr
🔹 Revenue Growth: Targeting ~30% in FY27
🔹 Railway Tenders: 6 major tenders coming up
🔹 Order Prospects: Currently sitting on ₹40,000 Cr opportunities

📌 Strong railway tender pipeline + defence & mining opportunities could support growth.

[Shivam Kumar @ShivamKumar509]

🚀 BAJEL PROJECTS: MEGA ORDER WIN!

Bajel Projects secures a mega EPC order for transmission line construction. ⚡

🔹 Order Value: ₹300–400 Cr
🔹 Segment: Power Transmission
🔹 Scope: EPC transmission line construction
🔹 Impact: Strengthens order book & revenue visibility
🔹 Sector: Power & Infrastructure 📈

⚡ Another strong order win for Bajel Projects!

#bajel_project #order

[Shivam Kumar @ShivamKumar509]

🚀 GLAND PHARMA: Strategic CDMO Partnership

Gland Pharma has entered into a strategic CDMO partnership with a leading global pharmaceutical company for sterile injectable manufacturing and supply.

🔹 Focus: Sterile injectable products
🔹 Business model: CDMO manufacturing & supply
🔹 Partner: Leading global pharmaceutical company
🔹 Potential benefit: Higher manufacturing capacity utilisation + long-term revenue visibility
🔹 Strategic impact: Strengthens Gland Pharma’s position in the global injectable CDMO market

Key takeaway:

🤝 A strategic CDMO tie-up could support Gland Pharma’s growth in high-value sterile injectables.

[Shivam Kumar @ShivamKumar509]

#zaggle_prepaid_ocean

📉 The chart is confirming what the shareholding data is telling us.

The stock is currently at ₹206 — and the technical setup remains weak.

📊 Technical Breakdown:

• Current Price: ₹206
• 50-DMA: ₹206 → Right at the short-term trend
• 100-DMA: ₹221 → ~7% below
• 200-DMA: ₹272 → ~24% below
• RSI: 48.9 → Neutral
• MACD: -0.92 → Slightly negative

⚠️ The biggest concern is the 200-DMA.

The stock is trading nearly 24% below its long-term trend line, showing that the broader trend is still bearish.

RSI at 48.9 doesn’t indicate panic selling or an oversold condition.

MACD is negative, but momentum isn’t collapsing sharply either..

[Shivam Kumar @ShivamKumar509]

🚨 The shareholding data tells the REAL story behind the stock’s fall.

The business may be doing fine — but institutional selling is a big warning sign. 📉

📊 Shareholding Change

• FIIs: 8.5% → 2.3% 🔻 6.2%
• Mutual Funds: 5.4% → 2.8% 🔻 2.6%
• Retail: 36.7% → 48.0% 🔺 11.3%

⚠️ FIIs have cut their stake by 6.2% in just one year.

At the same time, MFs have also reduced their holding.

So who is absorbing the selling?

👉 Retail investors.

The interesting part is that the business itself hasn’t collapsed. The company has continued to win major deals with Daimler, HPCL and PNB, while promoters also bought shares in June.

But sustained institutional selling can keep pressure on the stock even when the underlying business remains strong.

💡 The key question:

Are institutions selling because they see something retail investors are missing? Or is this simply a temporary shift in institutional allocation?

[Shivam Kumar @ShivamKumar509]

#zaggle_prepaid_ocean

🚨 The shareholding data tells the REAL story behind the stock’s fall.

The business may be doing fine — but institutional selling is a big warning sign. 📉

📊 Shareholding Change

• FIIs: 8.5% → 2.3% 🔻 6.2%
• Mutual Funds: 5.4% → 2.8% 🔻 2.6%
• Retail: 36.7% → 48.0% 🔺 11.3%

⚠️ FIIs have cut their stake by 6.2% in just one year.

At the same time, MFs have also reduced their holding.

So who is absorbing the selling?

👉 Retail investors.

The interesting part is that the business itself hasn’t collapsed. The company has continued to win major deals with Daimler, HPCL and PNB, while promoters also bought shares in June.

But sustained institutional selling can keep pressure on the stock even when the underlying business remains strong.

💡 The key question:

Are institutions selling because they see something retail investors are missing? Or is this simply a temporary shift in institutional allocation?

[Shivam Kumar @ShivamKumar509]

One of the biggest mistakes I made in swing trading was ignoring my stop loss.

When the market started falling, all my positions went down. I thought, “Every stock is falling, the market will recover soon.” Most of my stocks were fundamentally strong, so I decided to hold.

The market eventually recovered, but some of my stocks — Zaggle, Tatva Chintan, and EIEL — never recovered the way I expected. My capital remained stuck while other opportunities passed by.

Looking back, I realize that I should have exited when my stop loss was hit. A stop loss is not just a number; it’s a risk management tool that protects your capital.

This experience taught me a valuable lesson:

•Always respect your stop loss.
•Never let hope replace discipline.
•Capital protection is more important than being right.

No matter what happens in the market, the economy, or the country, risk management should always come first.

What’s the biggest trading lesson you’ve learned from your losses? 👇

#StockMarket #SwingTrading #RiskManagement #TradingPsychology #Investing #TraderLife

[Shivam Kumar @ShivamKumar509]

🚨 UPI REMAINS FREE FOR USERS! 🇮🇳

The Government has clarified that UPI payments remain free for users.

🔹 No MDR for customers
🔹 MDR applies only to certain large-merchant transactions
🔹 Government rejects fears of UPI becoming a paid service
🔹 Small merchants & users continue to benefit from free UPI payments

📲 UPI continues to remain a key part of India’s digital payments ecosystem.

#UPI #DigitalPayments #India #Fintech #UPIPayments

[Shivam Kumar @ShivamKumar509]

🚨 #UPI_CHARGES? BIG UPDATE FOR USERS 🇮🇳

Reports around proposed changes to India’s payment framework triggered concerns that UPI transactions could become chargeable, especially for higher-value payments.

🔹 MDR (Merchant Discount Rate) could be introduced/allowed for certain transactions
🔹 Large merchants were at the centre of the discussion
🔹 This sparked fears that UPI users could eventually be charged
🔹 No confirmation that regular users would have to pay for UPI

📲 The news quickly created confusion around the future of “FREE UPI”.

Would you still use UPI if charges were introduced? 👇

[Shivam Kumar @ShivamKumar509]

🚨 #UPI_CHARGES? BIG UPDATE FOR USERS 🇮🇳

Reports around proposed changes to India’s payment framework triggered concerns that UPI transactions could become chargeable, especially for higher-value payments.

🔹 MDR (Merchant Discount Rate) could be introduced/allowed for certain transactions
🔹 Large merchants were at the centre of the discussion
🔹 This sparked fears that UPI users could eventually be charged
🔹 No confirmation that regular users would have to pay for UPI

📲 The news quickly created confusion around the future of “FREE UPI”.

Would you still use UPI if charges were introduced? 👇

[Shivam Kumar @ShivamKumar509]

Strong quarter with PAT more than doubling YoY! 🔥

📌 Quick Breakdown:

• Sales: ₹945 Cr | ⬆️ 57% YoY
• EBIT: ₹91.5 Cr | ⬆️ 58% YoY
• Net Profit: ₹70.1 Cr | ⬆️ 109% YoY 🚀
• EPS: ₹20.22 | ⬆️ 109% YoY
• EBIT Margin: ~9.7%

🔥 Key takeaway:
Revenue grew strongly, but the biggest highlight was 109% YoY growth in net profit and EPS.